A: Vasoactin® is a brain nutrient that helps improve cognitive function and protects brain cells. It works by increasing the levels of key neurotransmitters such as acetylcholine, dopamine, and noradrenaline, which are essential for brain activity, memory, and learning. Additionally, Vasoactin® helps maintain the structure of neuronal cell membranes, ensuring proper communication between brain cells. It has shown neuroprotective effects, particularly in cases of reduced oxygen supply (hypoxia) and poor blood flow (ischemia). By restoring mitochondrial ATPase and Na+/K+ ATPase activity, it enhances brain energy metabolism, reduces inflammation, and accelerates the reabsorption of cerebral edema, which is swelling in the brain due to fluid accumulation. These benefits make Vasoactin® particularly useful in treating stroke, cognitive decline, and neurodegenerative diseases like Alzheimer’s and Parkinson’s disease.

A: Vasoactin® is primarily used to treat various cerebrovascular and neurological conditions. It is prescribed for patients who have suffered an ischemic stroke, as it helps accelerate recovery when taken within 24 hours of stroke onset. It is also used for cognitive decline due to stroke, memory loss, dizziness, and poor concentration resulting from head trauma or brain injuries. Additionally, Vasoactin® is beneficial in the treatment of degenerative brain diseases such as Alzheimer’s disease, as it helps slow cognitive decline and improves memory function. Another important use of Vasoactin® is in Parkinson’s disease, where it is often used as a co-therapy to enhance the effects of other Parkinson’s medications. It also helps with chronic cerebrovascular diseases, where blood flow to the brain is reduced over time, leading to issues like confusion and disorientation.

A: The dosage of Vasoactin® depends on the medical condition being treated and the patient’s overall health. For stroke treatment, Vasoactin® should be started within 24 hours of the stroke, with a dosage of 500–2000 mg per day. For patients experiencing cognitive decline after a stroke, the recommended dose is 1000–2000 mg per day. In cases of chronic cerebrovascular disease, 1000 mg per day is usually prescribed, divided into smaller doses and taken with or between meals. Vasoactin® is available in both tablet and injection forms. The injection can be administered intravenously or intramuscularly, with a dose of up to 1 g daily (1–2 injections per day). It is important to follow the prescribed dosage and consult a physician before making any adjustments to the treatment plan.

A: Vasoactin® is generally well tolerated, but like any medication, it may cause side effects in some patients. The most common side effects include dizziness, drowsiness, and a slight drop in blood pressure (hypotension). These effects occur due to the drug’s impact on the nervous system and blood circulation. Occasionally, Vasoactin® may stimulate the parasympathetic nervous system, leading to symptoms such as excessive sweating, nausea, or digestive discomfort. If the medication is administered too quickly, particularly in patients with intracranial hemorrhage, it may increase cerebral blood flow, potentially worsening the condition. In such cases, very slow administration (at 30 drops per minute) is recommended. It is important to report any unusual side effects to a doctor immediately, especially if they persist or worsen over time.

A: Yes, certain precautions must be taken while using Vasoactin®. It can cause dizziness and drowsiness, so patients should avoid operating machinery or driving while on this medication. Alcohol consumption should be strictly avoided, as it can enhance drowsiness and increase the risk of low blood pressure. Vasoactin® is not recommended for patients with hypertonia of the parasympathetic nervous system, as it may worsen their condition. Patients with a history of low blood pressure should also be cautious, as the medication may lower blood pressure further. If severe hypotension occurs, it can be managed with corticosteroids or sympathomimetic agents. Additionally, in cases of persistent intracranial hemorrhage, the drug should be administered very slowly to prevent excessive increases in cerebral blood flow. Patients should always follow their doctor’s recommendations and report any adverse effects promptly.

A: There is not enough reliable data to confirm whether Vasoactin® is completely safe for use during pregnancy and breastfeeding. Due to the lack of sufficient studies, doctors generally recommend using Vasoactin® only if the potential benefits outweigh the potential risks to the baby. Pregnant women should consult their physician before taking Vasoactin® to determine whether it is necessary for their condition. If the medication is prescribed, the patient should be closely monitored throughout the treatment. Similarly, for breastfeeding mothers, there is limited data on whether Vasoactin® passes into breast milk and affects the infant. Therefore, lactating women should either avoid the medication or seek medical advice before starting treatment. If any unusual symptoms occur in the mother or baby, the doctor should be informed immediately.